Response Assessment after Neoadjuvant Chemoradiotherapy in Rectal Cancer

Abstract

Management of locally advanced rectal cancer is complex, and magnetic resonance imaging (MRI) findings play a central role in treatment decisions. While neoadjuvant chemoradiotherapy significantly improved local recurrence rates, newer treatment modalities, such as total neoadjuvant chemotherapy, improved distant control. They significantly improved pathological complete response rates, enabling organ preservation in more patients. MRI is the best imaging modality to assess treatment response. MRI aids in assessing operability, predicts surgical outcomes following neoadjuvant treatment, and aids in identifying patients' eligible for organ preservation and their follow-up. In this review, we discuss imaging techniques and interpretation of rectal cancer MRI following neoadjuvant treatment, provide a structured reporting template for response assessment MRI, and detail how imaging findings influence treatment decisions.

Keywords

MRI - rectal cancer - MDT - restaging - neoadjuvant chemoradiotherapy

Ethical Approval and Consent to Participate

Not applicable.

Authors' Contributions

All authors contributed to the concept/design, a draft of the manuscript, and its editing. All authors read and approved the final manuscript. A.C. is the guarantor for the contents of the manuscript.

Publikationsverlauf

Artikel online veröffentlicht:
14. Februar 2025

• References

• 1 Iv AA, Koprowski MA, Nabavizadeh N, Tsikitis VL. The evolution of rectal cancer treatment: the journey to total neoadjuvant therapy and organ preservation. Ann Gastroenterol 2022; 35 (03) 226-233
• 2 Glynne-Jones R, Wyrwicz L, Tiret E. et al; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 04) iv22-iv40
• 3 Wei IH, Garcia-Aguilar J. Non-operative management of rectal cancer: understanding tumor biology. Minerva Chir 2018; 73 (06) 601-618
• 4 Temmink SJD, Martling A, Angenete E, Nilsson PJ. Complete response rates in rectal cancer: temporal changes over a decade in a population-based nationwide cohort. Eur J Surg Oncol 2023; 49 (11) 106991
• 5 Garcia-Aguilar J, Patil S, Gollub MJ. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40 (23) 2546-2556
• 6 Miranda J, Causa Andrieu P, Nincevic J. et al. Advances in MRI-based assessment of rectal cancer post-neoadjuvant therapy: a comprehensive review. J Clin Med 2023; 13 (01) 172
• 7 Patel UB, Taylor F, Blomqvist L. et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011; 29 (28) 3753-3760
• 8 Curcean S, Curcean A, Martin D. et al. The role of predictive and prognostic MRI-based biomarkers in the era of total neoadjuvant treatment in rectal cancer. Cancers (Basel) 2024; 16 (17) 3111
• 9 Smith HG, Nilsson PJ, Shogan BD. et al. Neoadjuvant treatment of colorectal cancer: comprehensive review. BJS Open 2024; 8 (03) zrae038
• 10 Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93 (10) 1215-1223
• 11 Ngan SY, Burmeister B, Fisher RJ. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30 (31) 3827-3833
• 12 Zhou ZR, Liu SX, Zhang TS. et al. Short-course preoperative radiotherapy with immediate surgery versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer: a systematic review and meta-analysis. Surg Oncol 2014; 23 (04) 211-221
• 13 Conroy T, Bosset JF, Etienne PL. et al; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (05) 702-715
• 14 Jin J, Tang Y, Hu C. et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 2022; 40 (15) 1681-1692
• 15 Bahadoer RR, Dijkstra EA, van Etten B. et al; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (01) 29-42
• 16 Dijkstra EA, Nilsson PJ, Hospers GAP. et al; Collaborative Investigators. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg 2023; 278 (04) e766-e772
• 17 Schrag D, Shi Q, Weiser MR. et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med 2023; 389 (04) 322-334
• 18 Basch E, Dueck AC, Mitchell SA. et al. Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT trial (Alliance N1048). J Clin Oncol 2023; 41 (21) 3724-3734
• 19 Deng Y, Chi P, Lan P. et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol 2016; 34 (27) 3300-3307
• 20 Deng Y, Chi P, Lan P. et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol 2019; 37 (34) 3223-3233
• 21 Mei WJ, Wang XZ, Li YF. et al. Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): initial results of a phase III trial. Ann Surg 2023; 277 (04) 557-564
• 22 Shen Y, Wu Q, Meng W, Wei M, Deng X, Wang Z. Neoadjuvant chemotherapy (CAPOX) alone for low- and intermediate-risk stage II/III rectal cancer: long-term follow-up of a prospective single-arm study. Eur J Surg Oncol 2023; 49 (12) 107115
• 23 Jayaprakasam VS, Alvarez J, Omer DM, Gollub MJ, Smith JJ, Petkovska I. Watch-and-wait approach to rectal cancer: the role of imaging. Radiology 2023; 307 (01) e221529
• 24 Fokas E, Appelt A, Glynne-Jones R. et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol 2021; 18 (12) 805-816
• 25 van der Valk MJM, Hilling DE, Bastiaannet E. et al; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018; 391 (10139): 2537-2545
• 26 West MA, Dimitrov BD, Moyses HE. et al. Timing of surgery following neoadjuvant chemoradiotherapy in locally advanced rectal cancer - a comparison of magnetic resonance imaging at two time points and histopathological responses. Eur J Surg Oncol 2016; 42 (09) 1350-1358
• 27 Nagtegaal ID, Glynne-Jones R. How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement. Cancer Treat Rev 2020; 84: 101964
• 28 Chen J, Wu Z, Zhang X. et al. Optimized tools and timing of response reassessment after neoadjuvant chemoradiation in rectal cancer. Int J Colorectal Dis 2022; 37 (11) 2321-2333
• 29 Jayaprakasam VS, Javed-Tayyab S, Gangai N. et al. Does microenema administration improve the quality of DWI sequences in rectal MRI?. Abdom Radiol (NY) 2021; 46 (03) 858-866
• 30 Chandramohan A, Siddiqi UM, Mittal R. et al. Diffusion weighted imaging improves diagnostic ability of MRI for determining complete response to neoadjuvant therapy in locally advanced rectal cancer. Eur J Radiol Open 2020; 7: 100223
• 31 Jang S, Lee JM, Yoon JH, Bae JS. Reduced field-of-view versus full field-of-view diffusion-weighted imaging for the evaluation of complete response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Abdom Radiol (NY) 2021; 46 (04) 1468-1477
• 32 Suthar M, Baheti AD, Ankathi SK. et al. MRI features of signet ring rectal cancer. Abdom Radiol (NY) 2021; 46 (12) 5536-5549
• 33 Patel UB, Blomqvist LK, Taylor F. et al. MRI after treatment of locally advanced rectal cancer: how to report tumor response–the MERCURY experience. AJR Am J Roentgenol 2012; 199 (04) W486-95
• 34 Santiago I, Barata M, Figueiredo N. et al. The split scar sign as an indicator of sustained complete response after neoadjuvant therapy in rectal cancer. Eur Radiol 2020; 30 (01) 224-238
• 35 Torri GB, Wiethan CP, Langer FW. et al. Split scar sign to predict complete response in rectal cancer after neoadjuvant chemoradiotherapy: systematic review and meta-analysis. Eur Radiol 2024; 34 (06) 3874-3881
• 36 Torkzad MR, Beets-Tan RGH. Importance and evolution of split scar sign. Eur Radiol 2024; 34 (06) 3872-3873
• 37 Beets-Tan RGH, Lambregts DMJ, Maas M. et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 2018; 28 (04) 1465-1475
• 38 Lee S, Kassam Z, Baheti AD. et al. Rectal cancer lexicon 2023 revised and updated consensus statement from the Society of Abdominal Radiology Colorectal and Anal Cancer Disease-Focused Panel. Abdom Radiol (NY) 2023; 48 (09) 2792-2806
• 39 Lambregts DMJ, Delli Pizzi A, Lahaye MJ. et al. A pattern-based approach combining tumor morphology on MRI with distinct signal patterns on diffusion-weighted imaging to assess response of rectal tumors after chemoradiotherapy. Dis Colon Rectum 2018; 61 (03) 328-337
• 40 Kokaine L, Gardovskis A, Gardovskis J. Evaluation and predictive factors of complete response in rectal cancer after neoadjuvant chemoradiation therapy. Medicina (Kaunas) 2021; 57 (10) 1044
• 41 Vliegen RFA, Beets GL, Lammering G. et al. Mesorectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction. Radiology 2008; 246 (02) 454-462
• 42 Patra A, Lakhani A, Augustine A. et al. Predicting positive radial margin on restaging MRI of patients with low rectal cancer: can we do better?. Indian J Radiol Imaging 2023; 34 (01) 85-94
• 43 Lord AC, Graham Martínez C, D'Souza N, Pucher PH, Brown G, Nagtegaal ID. The significance of tumour deposits in rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis. Eur J Cancer 2019; 122: 1-8
• 44 Lord AC, Knijn N, Brown G, Nagtegaal ID. Pathways of spread in rectal cancer: a reappraisal of the true routes to distant metastatic disease. Eur J Cancer 2020; 128: 1-6
• 45 Tan JJ, Carten RV, Babiker A, Abulafi M, Lord AC, Brown G. Prognostic importance of MRI-detected extramural venous invasion in rectal cancer: a literature review and systematic meta-analysis. Int J Radiat Oncol Biol Phys 2021; 111 (02) 385-394
• 46 Lord AC, D'Souza N, Shaw A. et al. MRI-diagnosed tumor deposits and EMVI status have superior prognostic accuracy to current clinical TNM staging in rectal cancer. Ann Surg 2022; 276 (02) 334-344
• 47 Chandramohan A, Mittal R, Dsouza R. et al. Prognostic significance of MR identified EMVI, tumour deposits, mesorectal nodes and pelvic side wall disease in locally advanced rectal cancer. Colorectal Dis 2022; 24 (04) 428-438
• 48 Schaap DP, Voogt ELK, Burger JWA. et al. Prognostic implications of MRI-detected EMVI and tumor deposits and their response to neoadjuvant therapy in cT3 and cT4 rectal cancer. Int J Radiat Oncol Biol Phys 2021; 111 (03) 816-825
• 49 Chand M, Swift RI, Tekkis PP, Chau I, Brown G. Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. Br J Cancer 2014; 110 (01) 19-25
• 50 Chand M, Heald RJ, Brown G. The importance of not overstaging mesorectal lymph nodes seen on MRI. Colorectal Dis 2013; 15 (10) 1201-1204
• 51 Shihab OC, Quirke P, Heald RJ, Moran BJ, Brown G. Magnetic resonance imaging-detected lymph nodes close to the mesorectal fascia are rarely a cause of margin involvement after total mesorectal excision. Br J Surg 2010; 97 (09) 1431-1436
• 52 Ogura A, Konishi T, Cunningham C. et al; Lateral Node Study Consortium. Neoadjuvant (Chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. J Clin Oncol 2019; 37 (01) 33-43
• 53 Ogura A, Konishi T, Beets GL. et al; Lateral Node Study Consortium. Lateral nodal features on restaging magnetic resonance imaging associated with lateral local recurrence in low rectal cancer after neoadjuvant chemoradiotherapy or radiotherapy. JAMA Surg 2019; 154 (09) e192172
• 54 Awiwi MO, Kaur H, Ernst R. et al. Restaging MRI of rectal adenocarcinoma after neoadjuvant chemoradiotherapy: imaging findings and potential pitfalls. Radiographics 2023; 43 (04) e220135
• 55 Gollub MJ, Lall C, Lalwani N, Rosenthal MH. Current controversy, confusion, and imprecision in the use and interpretation of rectal MRI. Abdom Radiol (NY) 2019; 44 (11) 3549-3558
• 56 Wnorowski AM, Menias CO, Pickhardt PJ, Kim DH, Hara AK, Lubner MG. Mucin-containing rectal carcinomas: overview of unique clinical and imaging features. AJR Am J Roentgenol 2019; 213 (01) 26-34
• 57 Huh JW, Park YA, Jung EJ, Lee KY, Sohn SK. Accuracy of endorectal ultrasonography and computed tomography for restaging rectal cancer after preoperative chemoradiation. J Am Coll Surg 2008; 207 (01) 7-12
• 58 Pastor C, Subtil JC, Sola J. et al. Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings?. Dis Colon Rectum 2011; 54 (09) 1141-1146
• 59 Marone P, de Bellis M, D'Angelo V. et al. Role of endoscopic ultrasonography in the loco-regional staging of patients with rectal cancer. World J Gastrointest Endosc 2015; 7 (07) 688-701
• 60 Martellucci J, Scheiterle M, Lorenzi B. et al. Accuracy of transrectal ultrasound after preoperative radiochemotherapy compared to computed tomography and magnetic resonance in locally advanced rectal cancer. Int J Colorectal Dis 2012; 27 (07) 967-973
• 61 Pomerri F, Pucciarelli S, Maretto I. et al. Prospective assessment of imaging after preoperative chemoradiotherapy for rectal cancer. Surgery 2011; 149 (01) 56-64
• 62 Kye BH, Kim HJ, Kim G, Kim JG, Cho HM. Multimodal assessments are needed for restaging after neoadjunvant chemoradiation therapy in rectal cancer patients. Cancer Res Treat 2016; 48 (02) 561-566
• 63 Benson AB, Venook AP, Al-Hawary MM. et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022; 20 (10) 1139-1167
• 64 Patel S, McCall M, Ohinmaa A, Bigam D, Dryden DM. Positron emission tomography/computed tomographic scans compared to computed tomographic scans for detecting colorectal liver metastases: a systematic review. Ann Surg 2011; 253 (04) 666-671
• 65 Crimì F, Valeggia S, Baffoni L. et al. [18F]FDG PET/MRI in rectal cancer. Ann Nucl Med 2021; 35 (03) 281-290
• 66 Wang J, Liu X, Hu B, Gao Y, Chen J, Li J. Development and validation of an MRI-based radiomic nomogram to distinguish between good and poor responders in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy. Abdom Radiol (NY) 2021; 46 (05) 1805-1815
• 67 Yu X, Song W, Guo D. et al. Preoperative prediction of extramural venous invasion in rectal cancer: comparison of the diagnostic efficacy of radiomics models and quantitative dynamic contrast-enhanced magnetic resonance imaging. Front Oncol 2020; 10: 459
• 68 Bedrikovetski S, Dudi-Venkata NN, Kroon HM. et al. Artificial intelligence for pre-operative lymph node staging in colorectal cancer: a systematic review and meta-analysis. BMC Cancer 2021; 21 (01) 1058
• 69 Horvat N, Veeraraghavan H, Khan M. et al. MR imaging of rectal cancer: radiomics analysis to assess treatment response after neoadjuvant therapy. Radiology 2018; 287 (03) 833-843